Lumos Pharma Inc

Lumos Pharma — NewLink Genetics — FY2015 Earnings Presentation

10 slides from Lumos Pharma's earnings presentation, Feb 29, 2016

  1. Slide 1: Fourth Quarter and Year-End 2015 Operational and Financial Results

    Fourth Quarter and Year-End 2015 Operational and Financial Results Nasdaq: NLNK February 29, 2016

  2. Slide 2: Agenda

    Agenda 2 Introduction  Mr. Jack Henneman, Executive Vice President & CFO Key 2015 Takeaways & 2016 Priorities  Dr. Charles J. Link, Chairman, CEO & CSO Highlights of 2015 - 2016 Clinical Programs  Dr. Nicholas N. Vahanian, President & CMO Fourth Quarter and Year-End 2015 Financial Results  Mr. J

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties and actual results may differ from expectations, estimates and projections and cons

  4. Slide 4: NewLink Genetics Programs

    4 NewLink Genetics Programs HyperAcute® Cellular Immunotherapies  Pancreatic  NSCLC  Advanced Melanoma  Prostate  Kidney IDO Pathway Inhibitors  Breast  Prostate  Pancreatic  Advanced Melanoma  Refractory Malignant Brain Tumors  Solid Tumors Infectious Diseases Ebola vaccine program Zika

  5. Slide 5: Key 2015 Takeaways

    Key 2015 Takeaways Exceptional Year with Strong Clinical & Pre-Commercial Advancements  IMPRESS trial advancing according to plan  Increased manufacturing and pre-commercialization efforts for algenpantucel-L  Made clinical progress in Phase 1 and Phase 2 trials for additional HyperAcute® Cellula

  6. Slide 6: 2016 Business Priorities

    2016 Business Priorities 6 Charles J. Link, Jr., Chairman, CEO, & CSO HyperAcute® Cellular Immunotherapy  IMPRESS Phase 3 – Report on top-line results – Execute on regulatory strategy with FDA – Continue U.S. commercialization planning – Explore partnering strategy outside U.S.  HyperAcute® Cellul

  7. Slide 7: Highlights of 2015 Clinical Programs

    Highlights of 2015 Clinical Programs 7 Nicholas Vahanian, M.D., President & Chief Medical Officer HyperAcute® Cellular Immunotherapy  HyperAcute® Cellular Immunotherapies continued to move forward with clinical programs in pancreatic, NSCLC, melanoma and kidney cancers  Completed enrollment of PIL

  8. Slide 8: Anticipated Highlights for 2016 Clinical Programs

    Anticipated Highlights for 2016 Clinical Programs 8 Nicholas Vahanian, M.D., President & Chief Medical Officer HyperAcute® Cellular Immunotherapies  Top-line results from the pivotal Phase 3 IMPRESS study  Update on the timing of results for the PILLAR study  Recently began enrollment in triple c

  9. Slide 9: Fourth Quarter and Year-End 2015 Financial Results

    Fourth Quarter and Year-End 2015 Financial Results 9 Jack Henneman, EVP and Chief Financial Officer Strong Capital Position  Stable and reliable cash position - $197.8M at YE 2015 / $202.8M at YE 2014  Goal and expectation to finish 2016 with two years of cash-on-hand Multiple Value Drivers Increa

  10. Slide 10: Q&A

    Brewin Q&A

NewLink Genetics — FY2015 Earnings Presentation on 6ix